受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系  

Research advances in the association of the tyrosine kinase receptor Axl and its ligand Gas6 with hepatocellular carcinoma

作　　者：吴雨[1] 钱平安[1] 范兴良[1] 祝峻峰[1] WU Yu;QIAN Ping’an;FAN Xingliang;ZHU Junfeng(Department of Hepatology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属市中医医院肝病科,上海201203

出　　处：《临床肝胆病杂志》2021年第1期184-187,共4页Journal of Clinical Hepatology

基　　金：上海市科学技术委员会科研计划项目(17401933600);上海市中医药新兴交叉学科资助计划(中医分子肝病学2017—2020);促进市级医院临床技能与临床创新能力三年行动计划项目(16CR3075B);中医优势病种培育项目(zybz-2017012)。

摘　　要：受体酪氨酸激酶Axl作为酪氨酸激酶受体之一,是上皮-间质转化的重要下游调节剂,与配体Gas6蛋白结合,通过激活下游信号转导途径,与肝细胞癌的血管侵袭、肿瘤转移和复发以及较低的存活率密切相关。目前针对Gas6/Axl信号通路的研究证实,Axl抑制剂在肝癌治疗中具有重要作用,是潜在的肝癌治疗靶点。主要介绍了Axl及配体Gas6与肝癌发生、发展的关系及在肝癌诊断和治疗中的应用,为早期诊断肝癌及抗癌治疗的临床研究提供新思路。As one of the tyrosine kinase receptors,Axl is an important downstream regulator of epithelial-mesenchymal transition(EMT)and can bind to its ligand Gas6 protein.By activating the downstream signal transduction pathways,Axl is closely associated with vascular invasion,tumor metastasis,recurrence,and low survival rate of hepatocellular carcinoma.Current studies on the Gas6/Axl signaling pathway have confirmed that Axl inhibitors play an important role in the treatment of liver cancer and the Gas6/Axl signaling pathway may be a potential therapeutic target for liver cancer.This article mainly introduces the association of Axl and its ligand Gas6 with the development and progression of liver cancer and their application in the diagnosis and treatment of liver cancer,in order to provide new ideas for the early diagnosis of liver cancer and clinical research on anti-cancer treatment.

关 键 词：癌 肝细胞 AXL 生长停滞特异性蛋白6 

分 类 号：R735.7[医药卫生—肿瘤]